Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kushner, Lauren E ^a   Wendelboe, Aaron M ^b   Lazzeroni, Laura C ^c   Chary, Aarthi ^a,c   Winters, Mark A ^a,c   Osinusi, Anu ^d   Kottilil, Shyam ^d   Polis, Michael A ^d   Holodniy, Mark ^a,c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BETA INTERFERON; CXCL1 CHEMOKINE; CYTOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCATTER FACTOR; UNINDEXED DRUG;

ADULT; AFRICAN AMERICAN; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RESPONSE; DRUG RESPONSE; DRUG TARGETING; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHARMACOLOGICAL PARAMETERS; PROTEIN ANALYSIS; SEX RATIO; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COINFECTION; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84875921454     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060387     Document Type: Article

References (43)

1. Wald O, Weiss ID, Galun E, Peled A, (2007) Chemokines in hepatitis C virus infection: Pathogenesis, prognosis and therapeutics. Cytokine 39: 50-62.
2. Bortolami M, Kotsafti A, Cardin R, Farinati F, (2008) Fas/FasL system, IL-1β expression and apoptosis in chronic HBV and HCV liver disease. Journal of Viral Hepatitis 15: 515-522.
3. Larrubia J, Benito-Martnez S, Calvino M, Sanz-de-Villalobos E, Parra Cid T, (2008) Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World Journal of Gastroenterology 14: 7149-7159.
4. Page E, Nelson M, Kelleher P, (2011) HIV and hepatitis C coinfection: pathogenesis and microbial translocation. Current opinion in HIV and AIDS 6: 472-477.
5. Heydtmann M, Adams D, (2009) Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 49: 676-688.
6. Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, et al. (2008) Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 22: 203-210.
7. Woitas RP, Rockstroh JK, Beier I, Jung G, Kochan B, et al. (1999) Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. AIDS 13: 1313-1322.
8. Graham C, Wells A, Liu T, Sherman K, Peters M, et al. (2005) Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 19: 767-773.
9. Bruno R, Sacchi P, Puoti M, Maiocchi L, Patruno S, et al. (2008) Pathogenesis of liver damage in HCV-HIV patients. AIDS reviews 10: 15-24.
10. De Lorenzo F, Collot-Teixeira S, Boffito M, Feher M, Gazzard B, et al. (2008) Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures. Current Medicinal Chemistry 15: 2991-2999.
11. Calmy A, Gayet Ageron A, Montecucco F, Nguyen A, Mach F, et al. (2009) HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23: 929-939.
12. Carr A, (2008) Pathogenesis of cardiovascular disease in HIV infection. Current Opinion in HIV & AIDS 3: 234-239.
13. Sudano I, Spieker LE, Noll G, Corti R, Weber R, et al. (2006) Cardiovascular disease in HIV infection. American Heart Journal 151: 1147-1155.
14. Farrugia P, Lucariello R, Coppola J, (2009) Human immunodeficiency virus and atherosclerosis. Cardiology in review 17: 211-215.
15. Iannello A, Samarani S, Debbeche O, Tremblay C, Toma E, et al. (2009) Role of interleukin-18 in the development and pathogenesis of AIDS. AIDS reviews 11: 115-125.
16. Mujawar Z, Rose H, Morrow M, Pushkarsky T, Dubrovsky L, et al. (2006) Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biology 4: e365-e365.
17. Triant V, Meigs J, Grinspoon S, (2009) Association of C-reactive protein and HIV infection with acute myocardial infarction. Journal of acquired immune deficiency syndromes 51: 268-273.
18. Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Medicine 5: e203-e203.
19. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, et al. (2007) FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46: 32-36.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR, (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases 40: 373-383.
21. Perneger TV, (1998) What's wrong with Bonferroni adjustments. BMJ British medical journal 316: 1236-1238.
22. Rothman KJ, (1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43-46.
23. Savitz DA, Olshan AF, (1995) Multiple comparisons and related issues in the interpretation of epidemiologic data. American journal of epidemiology 142: 904-908.
24. Thompson JR, (1998) Invited commentary: Re: "Multiple comparisons and related issues in the interpretation of epidemiologic data". American journal of epidemiology 147: 801-806.
25. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM, (1996) Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa. Hepatology 24: 6-9.
26. Fan XG, Liu WE, Li CZ, Wang ZC, Luo LX, et al. (1998) Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediators of inflammation 7: 295-297.
27. Wynn T, (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature reviews Immunology 4: 583-594.
28. Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, et al. (1995) An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376: 594-596.
29. Wasmuth H, Tacke F, Trautwein C, (2010) Chemokines in liver inflammation and fibrosis. Seminars in liver disease 30: 215-225.
30. Chaparro M, Sanz Cameno P, Trapero Marugan M, Garcia Buey L, Moreno Otero R, (2007) Mechanisms of angiogenesis in chronic inflammatory liver disease. Annals of hepatology 6: 208-213.
31. Fukuda R, Ishimura N, Ishihara S, Chowdhury A, Morlyama N, et al. (1996) Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver. 16: 390-399.
32. Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, et al. (2011) Interleukin-8 Is Activated in Patients with Chronic Liver Diseases and Associated with Hepatic Macrophage Accumulation in Human Liver Fibrosis. PLoS ONE 6: e21381.
33. Loskutoff DJ, Quigley JP, (2000) PAI-1, fibrosis, and the elusive provisional fibrin matrix. The Journal of clinical investigation 106: 1441-1443.
34. Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, et al. (2011) Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. European journal of clinical microbiology & infectious diseases 30: 761-766.
35. Farci P, Wollenberg K, Diaz G, Engle R, Lai M, et al. (2012) Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proceedings of the National Academy of Sciences of the United States of America 109: 14562-14567.
36. Panasiuk A, Prokopowicz D, Panasiuk B, (2004) Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C. World Journal of Gastroenterology. 10: 3639-3642.
37. Masiá M, Robledano C, López N, Escolano C, Gutiérrez F, (2011) Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and-uninfected patients. Journal of antimicrobial chemotherapy 66: 1861-1868.
38. Florholmen J, Kristiansen MG, Steigen SE, Sørbye SW, Paulssen EJ, et al. (2011) A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C. Clinical microbiology and infection. 17: 204-209.
39. Mϋhlbauer M, Bosserhoff A, Hartmann A, Thasler W, Weiss T, et al. (2003) A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125: 1085-1093.
40. Spengler U, Nattermann J, (2007) Immunopathogenesis in hepatitis C virus cirrhosis. Clinical science 112: 141-155.
41. Calabrese F, Pontisso P, Pettenazzo E, Benvegnù L, Vario A, et al. (2000) Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 31: 1153-1159.
42. Guzmn-Fulgencio M, Berenguer J, Garca-lvarez M, Micheloud D, C López J, et al. (2011) Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy. European journal of clinical microbiology & infectious diseases 30: 1213-1221.
43. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, et al. (2009) A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell 16: 295-308.